Open-Label Extension Study: Long-Term Data | TAKHZYRO® (lanadelumab-flyo)

https://stage--stage-takhzyro--onetakeda.aem.page/hcp/safety-profile/fragments/safety-header

Style

section-no-margin, section-no-padding

Style

Inner-content-contained, section-no-top-margin, section-no-bottom-margin, flex-stretch, section-no-top-padding, section-no-bottom-padding, pink-tertiary-btn

Consistent safety profile seen in 212 patients in the open-label extension study¹

Safety data of patients taking TAKHZYRO for an average of 30 months³

Most common ARs (≥10%) observed
in the HELP open-label study³

TAKHZYRO 300 mg every 2 weeks
(N=212)

Injection site pain

47%

Viral upper respiratory tract infection

42%

Upper respiratory tract infection

26%

Headache

25%

Injection site erythema

17%

Arthralgia

13%

Injection site bruising

12%

Back pain

12%

Diarrhea

11%

Sinusitis

11%

Influenza

10%

Nausea

10%

Urinary tract infection

10%

Mean study duration: 29.6 (SD=8.2) months.³

Hypersensitivity reactions (2%, n=4) were reported in the study.^3*

Six patients discontinued due to treatment-emergent adverse events.³

Three of the subjects discontinued due to hypersensitivity reactions³
One hypersensitivity event was considered related to the study drug and led to discontinuation³
No discontinuations due to injection site reactions, and most injection site reactions resolved within 1 hour (70.2%) or 1 day (92.6%)³
No treatment-related serious adverse events or anaphylaxis were observed³

*Related, treatment-emergent hypersensitivity reactions.³

Style

Inner-content-contained, section-no-top-margin, section-no-bottom-margin, section-no-bottom-padding, section-footnote, h4-magenta, section-safety-tabs

Explore more safety information

HELP STUDY

REAL WORLD EMPOWER STUDY

SPRING STUDY

Style

Inner-content-contained, section-no-bottom-margin, flex-stretch, section-no-bottom-padding, section-no-top-padding

https://stage--stage-takhzyro--onetakeda.aem.page/hcp/safety-profile/fragments/offers-info

Style

section-no-top-padding, section-no-bottom-margin, section-no-bottom-padding, background-lavender-light, inner-content-contained

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2025. 2. Banerji A, Riedl MA, Bernstein JA, et al. JAMA. 2018;320(20):2108-2121. doi:10.1001/jama.2018.16773 3. Banerji A, Bernstein JA, Johnston DT, et al; HELP OLE Investigators. Allergy. 2022;77(3):979-990. doi:10.1111/all.15011

Style

Inner-content-contained, section-references, section-no-top-margin, section-no-bottom-margin

https://main--takeda-eds-sites-takhzyro--onetakeda.hlx.page/hcp/fragments/isi

Style

Inner-content-contained, section-no-margin

important-safety-information

Consistent safety profile seen in 212 patients in the open-label extension study1

Safety data of patients taking TAKHZYRO for an average of 30 months3

Explore more safety information

Consistent safety profile seen in 212 patients in the open-label extension study¹

Safety data of patients taking TAKHZYRO for an average of 30 months³